Nottingham-based leading DMPK provider, XenoGesis, has been selected as a CRO partner to support the UK Medicines Discovery Catapult Virtual R&D Discovery Services platform worldwide.
Based at BioCity Nottingham, XenoGesis is one of 22 world-class CROs chosen for the partnerships by the UK government’s Medicines Discovery Catapult.
Part of a UK government initiative and promoted globally, the Catapults are a network of world-leading centres designed to transform the UK’s capability for innovation in specific areas and help drive future economic growth.
The Medicine’s Discovery Catapult is a new addition to this network and its Virtual R&D platform forms part of the UK’s Life Sciences Industrial Strategy, focused on maintaining the UK’s strength and increasing the pace of economic growth in this sector.
The Catapult’s partnerships aim is to boost UK life sciences R&D and international competitiveness by channelling high quality projects through best-in-class service providers.
Commenting on XenoGesis’ selection and the partnership, Rachel Hemsley, its Global Head of Business Development, said: “We’re delighted to be selected to support the Virtual R&D Discovery Services platform, which will benefit the hotbed of companies working in drug discovery in the UK.
“The partnership with the Medicines Discovery Catapult will enable us to provide DMPK and drug discovery support to its clients, who will benefit from our expertise, knowledge and services, and also reach new and international customers, and hopefully develop more and larger collaborations.”